While most of the cash for Swiss biotech firms comes from outside the country, around 20% is provided by Swiss entities. Scrip spoke with two of these home-grown supporters of life sciences innovation about the move from academia to industry and their respective investment strategies.
Despite the macroeconomic challenges that have beset the global life sciences sector, biotech firms in Switzerland together raised more than CHF1.3bn ($1.45bn) in 2022 according to the Swiss Biotech Association’s latest annual report. Around CHF780m of this was collected by public companies with the remaining CHF550m collected by privately held firms.
Roughly 80% of investment in financing rounds for Swiss biotech firms comes from foreign companies, but the remainder comes from...
Rumor mill suggests a $15bn licensing deal for ivonescimab is in the offing.
Emerging Company Profile: Early-stage biotech Eolo will seek cash and deals for its novel obesity drug SANA after positive Phase I results for weight loss, lean muscle mass preservation and fat mass reduction.
Multi-blockbuster falls short in a giant cell arteritis study.
